About us

We help scientists and entrepreneurs launch and build exceptional biotech companies

Our story

Since early 2018, BaseLaunch has supported nine ventures that have, in total, raised over $180 million in financing. Several collaborations have been initiated and one company has been sold. As of early 2020, we have added another four companies to our portfolio and have also been instrumental in contributing to the development of six more ventures in the Basel Area.

During our first phase (2017-2019), BaseLaunch partnered with Roche, Novartis Venture Fund, J&J, Pfizer and Roivant Sciences. As a result of our success, in May 2020 we launched our second phase, increasing the funding available up to $500,000 per company. The partners for the Phase II have been announced recently and include Roche, BB Pureos Bioventures, Roivant Sciences, Bridge Bioventures, CSL Behring, Johnson & Johnson.

BaseLaunch is managed and operated by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.

See our portfolio

Basel Area: A leading Life Sciences hub

The Basel Area is a biopharma hotspot. It is home to Roche and Novartis, two of the world’s largest pharmaceutical companies, as well as Actelion, now part of Johnson & Johnson, and formerly one of Europe’s most successful biotechs.

However, it is not just about big pharma. The Basel Area is a hotbed of innovation with numerous small to medium biotech companies, world class research institutions, marquee venture capitalists and several technology parks.

The tightly interwoven academic and biopharma environment feeds a tremendous flow of innovation in the Basel Area which is also reflected in the significant venture capital investments of over $2 billion that have been made in the last few years. This, together with the deep talent pool of the region, and the entrepreneur-friendly economic policies of Switzerland, makes the Basel Area the ideal breeding ground for new biopharma ventures.

BaseLaunch is deeply embedded within this ecosystem, while also being connected to the global biopharma community – and we utilize both networks for the benefit of the ventures we support.

Key facts

The Basel Area is a biopharma hotspot

  • 700+ companies
  • 32’000+ employees
  • 350+ drugs in clinical development
  • $4B+ public and private financings raised last few years

With close access to top biomedical research

  • $21B+ in research spending
  • 1000+ research groups
  • 13+ research institutes

Success stories

Some of our successes (click on the logo to learn more)

Read success stories